Xenon Pharmaceuticals Inc (XENE) Company Profile & Statistics

Xenon Pharmaceuticals Inc
XENE
(Nasdaq - US)
Closed
41.19
+1.39 (+3.49%)
in:usd•As of: Nov 22, 2024 15:59 UTC -5
Pre Market:0+0.00 (0.00%)
Open
40.01
High
41.55
Low
39.70

About Xenon Pharmaceuticals Inc

CEO

Ian Mortimer

Headquarters

200 - 3650 gilmore way

burnaby, a1 v5g 4w8, canada

Auditor

KPMG LLP

Employees

259

Share Holders

Website

www.xenon pharma.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.

Xenon Pharmaceuticals Inc Statistics

Valuation Measures

Market Capitalization ²	3.14B
Enterprise Value	3.05B
Enterprise Value/EBITDA (ttm)	-12.08
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	3.93
Price to Sales (ttm)	N/A
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	0.00%
Operating Margin (ttm)	N/A
Profit Margin (ttm)	0.00%
Return on Equity (ttm)	-24.69%
Return on Invested Capital (ttm)	-24.95%
Return on Assets (ttm)	-23.68%

Income Statement

Revenue (ttm)	0.00
Revenue Per Share (ttm)	0.00
Gross Profit (ttm)	0.00
EBITDA (ttm)³	-252.74M
Net Income Avi to Common (ttm)	-213.39M
Diluted EPS (ttm)	-2.82

Share Statistics

Beta (5Y Monthly)	1.25
52-Week Change	41.60%
S&P500 52-Week Change	31.18%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	76.24M
Dividend Yield	0.00%
Float ⁴	72.03M
% Held by Insiders	5.52%
% Held by Institutions	95.45%

Balance Sheet

Total Cash (mrq)	654.01M
Total Cash Per Share (mrq)	8.58
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	22.21%
Quick Ratio (mrq)	22.21%
Book Value Per Share (mrq)	10.53

Cash Flow

Operating Cash Flow Per Share (ytd)	-1.63
Free Cash Flow (ytd)	-129.30M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Xenon Pharmaceuticals Inc

Trade With A Regulated Broker